3D方案(帕里瑞韦/利托那韦/奥比他韦联合达塞布韦)治疗初治基因1b型慢性丙型肝炎患者的效果分析

王博文; 康文; 孙永涛; 贾战生; 谢玉梅

doi:10.3969/j.issn.1001-5256.2017.06.015

3D方案(帕里瑞韦/利托那韦/奥比他韦联合达塞布韦)治疗初治基因1b型慢性丙型肝炎患者的效果分析

DOI: 10.3969/j.issn.1001-5256.2017.06.015

第四军医大学唐都医院传染科

基金项目:

国家自然科学基金青年科学基金项目(81501041)；

详细信息

中图分类号: R512.63
计量
- 文章访问数: 372
- HTML全文浏览量: 57
- PDF下载量: 107
- 被引次数: 0
出版历程
- 收稿日期: 2017-01-13
- 出版日期: 2017-06-20

Clinical effect of 3D regimen (paritaprevir/ritonavir/ombitasvir combined with dasabuvir) in treatment-naive patients with genotype 1b chronic hepatitis C

Department of Infectious Diseases, Tangdu Hospital, Fourth Military Medical University

Research funding:

摘要

摘要: 目的观察3D方案（帕里瑞韦/利托那韦/奥比他韦联合达塞布韦）治疗初治基因1b型慢性丙型肝炎患者的临床疗效。方法纳入2015年9月-2016年4月就诊于第四军医大学唐都医院传染科初治的基因1b型慢性丙型肝炎患者10例。给予3D方案治疗12周,治疗结束后随访24周,观察治疗结束后12周和24周持续病毒学应答（SVR12和SVR24）情况,并监测生化学变化和不良反应发生情况。计量资料多组间比较采用方差分析。结果治疗2周,70%患者HCV RNA达到检测下限以下;治疗12周,100%患者HCV RNA检测不到,生化学应答率达100%。SVR12和SVR24均为100%。治疗期间和随访24周患者ALT、AST和炎症性指标干扰素诱导蛋白10均较治疗前显著下降（F值分别为20.15、10.83、13.67,P值均<0.05）。主要不良反应包括乏力和头痛,无严重不良事件。结论对于初治的基因1b型慢性HCV感染者,经3D方案治疗可获得极高的SVR率以及生化学应答率,并可改善患者肝功能,且具有良好的安全性。
- 肝炎,丙型,慢性 /
- 抗病毒药 /
- 治疗
Abstract: Objective To investigate the clinical effect of 3D regimen (paritaprevir/ritonavir/ombitasvir combined with dasabuvir) in treatment-naive patients with genotype 1b chronic hepatitis C. Methods A total of 10 patients with genotype 1b chronic hepatitis C who were treated for the first time in Department of Infectious Diseases in our hospital from September 2015 to April 2016 were enrolled. All patients were treated with 3D regimen for 12 weeks and followed up for 24 weeks after treatment. Sustained virologic response at 12 and 24 weeks (SVR12 and SVR24) was observed, and the changes in biochemical parameters and the incidence of adverse events were monitored. An analysis of variance was used for comparison of continuous data between groups. Results After 2 weeks of treatment, 70% of all patients achieved an HCV RNA level reduced to below the detection level, and after 12 weeks of treatment, HCV RNA was not detected in any patient, resulting in a biochemical response rate of 100%. Both SVR12 and SVR24 were 100%. There were significant reductions in the levels of alanine aminotransferase, aspartate aminotransferase, and the inflammatory marker interferon-inducible protein 10 after treatment (F =20. 15, 10. 83, and 13. 67, all P < 0. 05) . The most common adverse events were weakness and headache and no serious adverse events were observed. Conclusion In treatment-naive patients with genotype 1b chronic hepatitis C, 3D regimen achieves high SVR rate and biochemical response rate, improves patients' liver function, and has good safety.
- hepatitis C, chronic /
- antiviral agents /
- therapy

HTML全文

参考文献(19)

[1]AN ZY, SHENG QJ, ZHANG C, et al.Early efficacy and safety of direct-acting antiviral agents for the treatment of cirrhotic patients with hepatitis C[J].Infect Dis Info, 2016, 29 (2) :81-84. (in Chinese) 安子英, 盛秋菊, 张翀, 等.直接抗病毒药物治疗丙型肝炎肝硬化早期抗病毒疗效及安全性临床实践研究[J].传染病信息, 2016, 29 (2) :81-84.

[2]NEUKAM K, MORANO-AMADO LE, RIVERO-JUAREZ A, et al.Liver stiffness predicts the response to direct-acting antiviralbased therapy against chronic hepatitis C in cirrhotic patients[J].Eur J Clin Microbiol Infect Dis, 2017, 36 (5) :853-861.

[3]SUAREZ BA, GONZALEZ-CORVILLO C, SOUSA JM, et al.Hepatitis C virus in kidney transplant recipients:a problem on the path to eradication[J].Transplant Proc, 2016, 48 (9) :2938-2940.

[4]LI T, QU Y, GUO Y, et al.Efficacy and safety of DAA-based antiviral therapies for HCV patients with stage 4-5 chronic kidney disease:a meta-analysis[J].Liver Int, 2016.[Epub ahead of print]

[5]GALLEGOS-OROZCO JF, KIM R, THIESSET HF, et al.Early results of pilot study using hepatitis C virus (HCV) positive kidneys to transplant HCV infected patients with end-stage renal disease allowing for successful interferon-free direct acting antiviral therapy after transplantation[J].Cureus, 2016, 8 (11) :e890.

[6]MINAEI AA, KOWDLEY KV.Paritaprevir/ritonavir and ombitasvir in combination with dasabuvir for the treatment of hepatitis C virus[J].Expert Opin Pharmacother, 2015, 16 (6) :929-937.

[7]GAMAL N, VITALE G, ANDREONE P.ABT-450:a novel agent for the treatment of CHC genotype 1:focus on treatment-experienced patients[J].Expert Rev Anti Infect Ther, 2015, 13 (3) :295-304.

[8]MARTEL-LAFERRIERE V.Paritaprevir/r-ombitasvir and dasabuvir with ribavirin eliminates viraemia in most patients with HCV infection with cirrhosis[J].Evid Based Med, 2015, 20 (1) :6.

[9]JU W, YANG S, FENG S, et al.Hepatitis C virus genotype and subtype distribution in Chinese chronic hepatitis C patients:nationwide spread of HCV genotypes 3 and 6[J].Virol J, 2015, 12:109.

[10]MCHUTCHISON JG.Hepatitis C advances in antiviral therapy:what is accepted treatment now?[J].J Gastroenterol Hepatol, 2002, 17 (4) :431-441.

[11]RANIERI R, STARNINI G, CARBONARA S, et al.Management of HCV infection in the penitentiary setting in the direct-acting antivirals era:practical recommendations from an expert panel[J].Infection, 2017, 45 (2) :131-138.

[12]YAN J.Changes in the diagnosis and treatment of hepatitis C in the era of direct antiviral drugs:some thought on the study of the guidelines for prevention and treatment of hepatitis C (2015 Edition) [J/CD].Chin J Liver Dis:Electronic Edition, 2015, 7 (4) :1-2. (in Chinese) 闫杰.直接抗病毒药物时代的丙型肝炎诊治有何改变:研读《丙型肝炎防治指南 (2015年更新版) 》后的几点思考[J/CD].中国肝脏病杂志:电子版, 2015, 7 (4) :1-2.

[13]FERENCI P, BERNSTEIN D, LALEZARI J, et al.ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV[J].N Engl J Med, 2014, 370 (21) :1983-1992.

[14]VEENHUIS RT, ASTEMBORSKI J, CHATTERGOON MA, et al.Systemic elevation of proinflammatory interleukin 18 in HIV/HCV coinfection versus HIV or HCV monoinfection[J].Clin Infect Dis, 2016, 13:544-556.

[15]CHEN YMS, BURCHELL J, SKINNER N, et al.Toll-like receptor expression and signaling in peripheral blood mononuclear cells correlate with clinical outcomes in acute hepatitis C virus infection[J].J Infect Dis, 2016, 214 (5) :739-747.

[16]YOUNOSSI ZM, TANAKA A, EGUCHI Y, et al.The impact of hepatitis C virus outside the liver:Evidence from Asia[J].Liver Int, 2016, 56 (7) :777-785.

[17]GRAGNANI L, PILUSO A, URRARO T, et al.Virological and clinical response to interferon-free regimens in patients with HCV-related mixed cryoglobulinemia:preliminary results of a prospective pilot study[J].Curr Drug Targets, 2016, 9 (8) :57-61.

[18]LUBETZKY M, CHUN S, JOELSON A, et al.Safety and efficacy of treatment of hepatitis C in kidney transplant recipients with directly acting antiviral agents[J].Transplantation, 2016, 42 (33) :54-59.

[19]OBERG CL, HIENSCH RJ, POOR HD.Ombitasvir-paritaprevir-ritonavir-dasabuvir (Viekira Pak) -induced lactic acidosis[J].Crit Care Med, 2017, 45 (3) :e321-e325.

施引文献

资源附件(0)

访问统计